What would you offer for a very young patient with metastatic renal medullary carcinoma who has progressed on cisplatin-based chemotherapy (with gemcitabine and paclitaxel)?  

Doxorubicin-based regimens (per our study here) adapted to context and EGFR-targeted therapies (see here but do not use bevacizumab as discussed here and here) with prioritization for panitumumab-based therapy as discussed here (from 5:00 onwards) and in yesterday's IKCS: NA session on rare kidn...